Objective-We have shown that the chloride-proton antiporter chloride channel-3 (ClC-3) is required for endosome-dependent signaling by the Nox1 NADPH oxidase in SMCs. In this study, we tested the hypothesis that ClC-3 is necessary for proliferation of smooth muscle cells (SMCs) and contributes to neointimal hyperplasia following vascular injury. Methods and Results-Studies were performed in SMCs isolated from the aorta of ClC-3-null and littermate control (wild-type [WT]) mice. Thrombin and tumor necrosis factor-␣ (TNF-␣) each caused activation of both mitogen activated protein kinase extracellular signal-regulated kinases 1 and 2 and the matrix-degrading enzyme matrix metalloproteinase-9 and cell proliferation of WT SMCs. Whereas responses to thrombin were preserved in ClC-3-null SMCs, the responses to TNF-␣ were markedly impaired. These defects normalized following gene transfer of ClC-3. Carotid injury increased vascular ClC-3 expression, and compared with WT mice, ClC-3-null mice exhibited a reduction in neointimal area of the carotid artery 28 days after injury. Conclusion-ClC-3 is necessary for the activation of SMCs by TNF-␣ but not thrombin. Deficiency of ClC-3 markedly reduces neointimal hyperplasia following vascular injury. In view of our previous findings, this observation is consistent with a role for ClC-3 in endosomal Nox1-dependent signaling. These findings identify ClC-3 as a novel target for the prevention of inflammatory and proliferative vascular diseases. (Arterioscler Thromb Vasc Biol. 2011;31:345-351.)
T here is widespread appreciation that atherosclerosis is a chronic inflammatory disease. 1 Proliferation of smooth muscle cells (SMCs) is fundamental to the development of vascular diseases, including arteriosclerosis, restenosis, and bypass graft failure. 2, 3 In addition to cell division, these processes require SMCs to secrete proteases to degrade extracellular matrix and facilitate the subsequent migration of cells from the media into the forming neointima. A variety of signaling molecules have been implicated in stimulating SMCs to undergo this process.
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Thrombin is a serine protease in the clotting cascade that converts soluble fibrinogen to insoluble fibrin. Thrombin also cleaves and activates the G-protein-coupled protease-activated receptor 1, which causes proliferation and increased motility via activation of the epidermal growth factor receptor (EGFR). 4, 5 Protease-activated receptor 1 activation contributes to the pathogenesis of atherosclerosis and restenosis via a variety of mechanisms, 6 many of which are mediated via activation of the EGFR. 4 Mice deficient in the protease-activated receptor 1 receptor display an altered response to vascular injury. 7 The proinflammatory cytokine tumor necrosis factor-␣ (TNF-␣) localizes to areas of arterial injury 8, 9 and contributes to development of neointimal hyperplasia. 10, 11 Although macrophages are a primary source of cytokines, vascular endothelium and SMCs also secrete TNF-␣. 12, 13 On exposure to TNF-␣, quiescent SMCs express matrix metalloproteinases (MMPs) and increase migration and proliferation by intracellular signaling pathways which involve activation of the transcription factor nuclear factor-B (NF-B). 14, 15 Animals lacking TNF-␣ display remarkably reduced activation of NF-B and neointima formation after carotid injury. 10 ClC-3 is a member of the CLC family of chloride-transporting proteins, which includes both anion channels (ClC-1 and ClC-2) and Cl Ϫ /H ϩ antiporters (ClC-3 through 7). 16 ClC-3 is present in all cell types and localized in plasma membranes and in intracellular vesicles. [17] [18] [19] In early endosomes of SMCs and in secretory vesicles of neutrophils, ClC-3 is necessary for activation of NADPH oxidase by cytokines. 20 -22 We have recently demonstrated that both thrombin and TNF-␣ signaling are dependent on production of reactive oxygen species (ROS) via activation of the Nox1 NADPH oxidase. 23 Nox1 plays an essential role in SMC proliferation, motility, and the inflammatory cascade associated with NF-B activation. It is therefore not surprising that Nox1 signaling contributes to neointima development after acute vascular injury. 24 However, we have demonstrated that the mechanism and subcellular location of Nox1 activation by thrombin and TNF-␣ is very different. Whereas TNF-␣ induces a Nox1-dependent, ClC-3-dependent, endosomal generation of intracellular ROS, thrombin activates Nox1 such that ROS does not occur within endosomes and does not require ClC-3. 23 We have proposed that ClC-3 provides charge neutralization for the NADPH oxidase electron current that is required for generation of ROS in signaling endosomes following cytokine activation. 20, 25, 26 On the basis of these findings, we hypothesized that ClC-3 is critical to the activation of SMCs by TNF-␣ but not to thrombin. We therefore determined whether ClC-3 was required for activation of extracellular signal-regulated kinases 1 and 2 (ERK1/2) and MMP-9 or for cell proliferation in response to thrombin or TNF-␣. In addition, because the contribution of ClC-3 to the development of vascular disease has not been previously tested, we assessed the requirement of this protein for neointimal hyperplasia following carotid injury.
Materials and Methods
A full description of all methods can be found in the Supplemental Materials, available online at http://atvb.ahajournals.org. SMCs were isolated from aorta of mice lacking the Clcn3 gene encoding ClC-3 chloride channels 27 (ClC-3-null) and from wild-type (WT) littermate controls as previously described. 20 For experiments, SMCs were serum deprived (0.5% serum) for 24 hours before stimulation with TNF-␣ (10 ng/mL) or thrombin (2 U/mL). The long N-terminal isoform of human ClC-3 (P51790) was polymerase chain reaction amplified and cloned into the adenovirus shuttle plasmid pacAd5 cytomegalovirus behind the cytomegalovirus promoter and used for reconstitution of ClC-3 expression in the null cells. Cell proliferation was determined by measuring [ 3 H]thymidine incorporation. MMP activity within the media was measured by gelatin zymography. The blood flow cessation model was used to induce carotid neointimal hyperplasia as previously described 28 in ClC-3-null and littermate 
Results

Role of ClC-3 in Proliferation of SMCs
In response to either thrombin or TNF-␣, WT SMCs increased [ 3 H]thymidine incorporation more than 2-fold. In contrast, SMCs deficient in ClC-3 responded similarly to thrombin but failed to respond to TNF-␣ ( Figure 1A and 1B). However, adenovirus-mediated gene transfer of ClC-3 to ClC-3-null SMCs normalized [ 3 H]thymidine incorporation in response to TNF-␣ ( Figure 1C ), suggesting a requirement for ClC-3 in TNF-␣-mediated proliferation. The overexpression of ClC-3 in WT SMCs increased [ 3 H]thymidine uptake under basal conditions without affecting the maximal response to TNF-␣ ( Figure 1C ). Further supporting a role for ClC-3 in SMCs growth, the chloride channel inhibitor niflumic acid (NFA, 0.3 mmol/L) inhibited TNF-␣-dependent [ 3 H]thymidine incorporation in WT SMCs (2.1Ϯ0.3 versus 0.2Ϯ0.1 for dimethyl sulfoxideϩTNF-␣ versus NFAϩTNF-␣, nϭ4, PϽ0.05).
Role of ClC-3 in Secretion of MMP-9
As detected by gelatin zymography, MMP-9 activity in the culture media increased when SMCs were treated for 24 hours with thrombin ( Figure 2A ) or TNF-␣, respectively ( Figure 2B ). SMCs deficient in ClC-3 responded normally to thrombin but failed to produce the normal increase in MMP-9 activity in response to TNF-␣. This response was corrected following gene transfer of ClC-3 ( Figure 2B ). Consistent with these observations, pretreatment of WT SMCs with NFA markedly inhibited TNF-␣-induced MMP-9 activation (4.2Ϯ0.3 versus 0.7Ϯ0.1 for dimethyl sulfoxideϩTNF-␣ versus NFAϩTNF-␣, nϭ4, PϽ0.05).
We next confirmed that these observations reflected changes in MMP-9 activation and not in expression by ClC-3-null SMCs. WT and ClC-3-null mice were serum deprived for 24 hours before stimulation with TNF-␣ or thrombin for 24 hours, and cells were collected for real-time polymerase chain reaction and Western blotting. There were no differences in the mRNA levels of MMP-9 between the genotypes and treatments (nϭ4, data not shown). Expression of MMP-9 protein was also similar in untreated WT and ClC-3-null cells ( Figure 2C ). Following TNF-␣ and thrombin treatment, protein levels of MMP-9 were reduced in WT cells, consistent with its secretion into the media (as shown in Figure 2A and 2B). In contrast, expression of MMP-9 by ClC-3-deficient cells was not significantly reduced by TNF-␣.
Role of ClC-3 in TNF-␣-Induced Activation of ERK1/2
Thrombin and TNF-␣ have been previously shown to activate multiple signaling pathways in SMCs, including ERK1/2. 29, 30 We tested the hypothesis that ClC-3 is necessary for activation of ERK1/2 by these agonists. Five minutes after treatment of SMCs with thrombin ( Figure 3A) , phosphorylation of ERK1/2 was increased approximately 2-fold. This effect was unaltered in cells lacking ClC-3. In response to TNF-␣ ( Figure 3B ), phosphorylation of ERK1/2 was increased in WT SMCs, but ClC-3-null SMCs did not respond. To exclude a delay in signaling, we also found that TNF-␣ failed to activate ERK1/2 in ClC-3-null SMCs at 10 and 15 minutes after stimulation (data not shown). However, adenovirus- mediated gene transfer of ClC-3 rescued activation of ERK1/2 in ClC-3-deficient SMCs ( Figure 3B ). Furthermore, NFA inhibited TNF-␣-induced ERK1/2 activation in WT SMCs (1.7Ϯ0.1 versus 0.6Ϯ0.1 for dimethyl sulfoxideϩ TNF-␣ versus NFAϩTNF-␣, nϭ4, PϽ0.05).
We next examined the role of ERK1/2 in cell proliferation and activation of MMP-9 in SMCs following stimulation by TNF-␣. The mitogen acitvated protein kinase (MEK) 1/2 inhibitor U0126 31 reduced baseline [ 3 H]thymidine incorporation and prevented the proliferative response to TNF-␣ in WT SMCs ( Figure 3C ). Overexpression of ClC-3 failed to restore proliferation in the presence of MEK1/2 inhibition (data not shown). U0126 had a similar effect on MMP-9 activation ( Figure 3D ), which is consistent with previous reports. 32 Taken together, these observations suggest that in response to TNF-␣, ClC-3 is proximal to activation of ERK1/2, which is necessary for the signaling of proliferation and MMP-9 activation.
Role of ClC-3 in Neointimal Hyperplasia
Expression of Nox1 is increased early after balloon injury of rat arteries and remains elevated in association with the development of neointima. 33 We recently demonstrated that activation of NF-B by Nox1 requires ClC-3. 20 Therefore, we next examined expression of ClC-3 in vascular tissues following cytokine activation or vascular injury. SMC expression of ClC-3 increased more than 3-fold following exposure to TNF-␣ ( Figure 4A ). Extending these observations in vivo, the left carotid artery was ligated in mice as a model of neointimal hyperplasia. 28 Ten days following surgery, which is before the development of neointima, 34 ClC-3 expression was increased Ϸ2.5-fold in the injured carotid artery, as compared with the contralateral noninjured artery ( Figure 4B ).
The observation that SMCs modulate expression of ClC-3 in response to cytokines and vascular injury, together with our findings that SMCs are dependent on ClC-3 for cellular signaling, matrix degradation, and proliferation, suggests a role for ClC-3 in the vascular response to injury. To test this hypothesis, we performed carotid ligation in WT and ClC-3null mice. Twenty-eight days following ligation, WT mice developed a robust neointima that was markedly attenuated in the ClC-3-null mice ( Figure 5A ). Deficiency of ClC-3 resulted in significant reduction in intimal area (Figure 5B ) and the intima:media ratio ( Figure 5C ) as compared with WT mice. Flow-induced outward remodeling is characteristic of the right carotid artery after ligation of the left carotid. 35 The external elastic lamina perimeter was greater in ClC-3-null mice as compared with WT mice (1.08Ϯ0.01 versus 1.01Ϯ 0.02, nϭ6, PϽ0.01).
Discussion
Inflammation, matrix remodeling, and SMC proliferation are key features in the development of atherosclerosis, restenosis after angioplasty, vein-graft stenosis, and transplant arteriosclerosis. In this study, we show that exposure of cultured SMCs to thrombin or TNF-␣ enhances secretion of the matrix degrading enzyme MMP-9, activates the mitogen-activated protein kinase signaling cascade ERK1/2, and increases cell proliferation. The primary novel finding of this study is the specific and distinct requirement for the ClC-3 Cl Ϫ /H ϩ antiporter in mediating these effects. Whereas responses to thrombin are maintained, those to TNF-␣ are markedly attenuated in SMCs deficient in ClC-3. Overexpression of ClC-3 augments the growth of WT SMCs, carotid injury induces vascular expression of ClC-3, and neointima development is impaired after carotid injury in ClC-3-null mice. These observations demonstrate a role for ClC-3 in agonistspecific activation of SMCs and provide the first evidence that ClC-3 contributes to neointimal hyperplasia in response to vascular injury. Our results identify ClC-3 as a potential therapeutic target in inflammatory and proliferative vascular disease.
The majority of ClC-3 protein is localized intracellularly but cycles through the plasma membrane, where it has a half-life of less than 10 minutes in resting cells. 36 In various cell types, ClC-3 has been localized to intracellular vesicles 20,37-39 and proposed to act as an anion channel and regulate vesicular acidification by providing charge neutralization for the V-ATPase proton pump. 37, 40 However, we have recently provided direct evidence that ClC-3 is an antiporter 25, 41 and have proposed that ClC-3 is required for charge neutralization of electron flow through the NADPH oxidase when generation of ROS is within vesicles. 20, 26 NADPH oxidases are a primary source of signaling ROS in vascular cells that activate both normal physiological and pathological processes. We have identified spatially distinct pathways of Nox1 activation and ROS production by TNF-␣ and thrombin. 23 Whereas TNF-␣ results in dynamindependent Nox1 generation of ROS within early endosomes, Nox1 activation by thrombin involves extracellular shedding of epidermal growth factor-like ligands and activation of the receptor tyrosine kinase EGFR independent of endocytosis. It is expected that these distinct differences in activation of Nox1 provide specificity in cell signaling, possibly distinguishing between inflammatory and noninflammatory stimuli. Activation of G-protein-coupled receptors causes shedding of ligands and subsequent transactivation of EGFR. 4 This process may represent a feed-forward mechanism necessary for amplification of intracellular ROS production and cell signaling. 42 Activation of mitogen-activated protein kinases is central to initiating cellular responses in vascular injury. ERK is rapidly phosphorylated in balloon-injured arteries 43 and has been shown to be important in the activation of MMP-9 and in cell proliferation. 32 This was confirmed by our observation that inhibition of ERK phosphorylation with U0126, a selective pharmacological inhibitor of MEK, prevented the TNF-␣-dependent increase in MMP-9 and [ 3 H]thymidine incorporation by SMCs. Further highlighting the importance of ERK in vascular injury, gene transfer of WT ERK increased, whereas gene transfer of a dominant-negative mutant ERK decreased neointimal hyperplasia in carotid arteries following balloon injury. 44 On the basis of pharmacological effects of anion channel blockers, anion currents have long been linked to proliferation of multiple cell types. 45 Reduction of ClC-3 protein levels using antisense oligonucleotides decreased proliferation of SMCs in response to ET-1, and ClC-3 mRNA expression was proportional to [ 3 H]thymidine incorporation. 46 The current work supports these observations, because ClC-3-null cells clearly display impaired TNF-␣-induced proliferation. We extend these observations in vivo and show reduced neointima formation in ClC-3-null mice following vascular injury.
In addition, we found that ClC-3 expression increased in cultured SMCs and in carotid arteries following TNF-␣ and carotid ligation, respectively. This is consistent with the previous report that ClC-3 expression is increased in SMCs of pulmonary arteries from rats with experimental pulmonary hypertension and following incubation with endothelin-1, platelet-derived growth factor, and interleukin-1␤. 47 These observations suggest that changes in ClC-3 expression or activity may be central in the regulation of cell growth.
Proliferation of SMCs in response to cytokines, including TNF-␣, plays an important role in the formation of atherosclerotic and restenotic lesions. 1,3 TNF-␣ activates the transcription factor NF-B, which is widely recognized as a key regulatory step in vascular inflammation. 48 In vivo transfection of NF-B decoy oligodeoxynucleotides into rat carotid artery inhibits neointimal formation after injury. 49 We previously showed that NF-B activation was markedly inhibited in ClC-3-null cells, and that the defect was a function of impaired ROS production following cytokine stimulation. 20 The current data showing defects in ERK1/2 and MMP-9 activation as well as proliferation are consistent with prior results. ERK1/2 activation is linked to ROS production, 50 and as we have demonstrated here, ERK1/2 is upstream of MMP-9 activation and proliferation.
The responses to vascular injury are complex and dependent on the model studied. The most commonly used murine Figure 6 . Proposed role for ClC-3 in the activation of SMCs. TNF-␣ causes Nox1 generation of ROS into endosomes, whereas thrombin increases intracellular ROS via EGFR activation. 23 ClC-3 is necessary for ERK1/2 phosphorylation, MMP-9 activation, and cell proliferation in response to TNF-␣ but not thrombin. This observation is consistent with a Cl Ϫ /H ϩ antiporter function of ClC-3 to provide charge neutralization for Nox1 generation of endosomal ROS. 20, 26 models to induce neointimal hyperplasia are perivascular cuff, wire injury, and carotid ligation. A potential limitation of our in vivo findings is that ligation results in cessation of blood flow and thrombus formation, which may activate cellular processes distinct from models of mechanical injury. Nevertheless, vascular lesions in humans often develop at sites of low shear stress, 51 and the carotid ligation model has advantages of reproducibility and simplicity.
In summary, this study presents in vitro data supporting a role for the chloride antiporter ClC-3 in MMP-9 activation and SMC proliferation via impaired TNF-␣-mediated activation of ERK1/2 ( Figure 6 ). In addition, in vivo data demonstrate that deficiency of ClC-3 inhibits neointimal hyperplasia in a model of carotid injury. Based on these observations, we propose that ClC-3 is a new therapeutic target for the prevention of vascular disease.
